Minimizing nephrotoxicity during multidrug-resistant tuberculosis treatment by the stepwise de-escalation of second-line injectables dosing intervals

Clin Microbiol Infect. 2022 May;28(5):752-754. doi: 10.1016/j.cmi.2022.01.023. Epub 2022 Feb 3.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Extensively Drug-Resistant Tuberculosis* / drug therapy
  • Humans
  • Mycobacterium tuberculosis*
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Antitubercular Agents